Polyclonal Antibody to Glucosidase Alpha, Acid (GaA)
| Code | Size | Price |
|---|
| PAA177Ra02-20ul | 20ul | £86.00 |
Quantity:
| PAA177Ra02-100ul | 100ul | £158.00 |
Quantity:
| PAA177Ra02-200ul | 200ul | £214.00 |
Quantity:
| PAA177Ra02-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
LYAG; Acid Alpha-Glucosidase; Lysosomal Alpha-Glucosidase; Pompe Disease Glycogen Storage Disease Type II; Acid Maltase; Aglucosidase Alfa
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Glucosidase Alpha, Acid
Reactivity:
Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml<br/>Immunohistochemistry in paraffin section: 5-20ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Glucosidase Alpha, Acid (GaA) | RPA177Ra02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||